Trials / Withdrawn
WithdrawnNCT00934401
Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer
Positron Emission Mammography With 3'-Deoxy-3'-[18F] Fluorothymidine (FLT PEM) for Evaluation of Response to Neoadjuvant Chemotherapy in Breast Cancer
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- University of Iowa · Academic / Other
- Sex
- Female
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Positron Emission Tomography Imaging with 3-Deoxy-3'-\[18F\]Fluorothymidine (FLT) can selectively identify proliferating and non-proliferating tissues, including tumors. FLT uptake in the tumor is an indirect marker of DNA synthesis activity, which is a target of chemotherapy. Our hypothesis is that early change in FLT uptake in tumor with chemotherapy will predict pathological response to neoadjuvant therapy in breast cancer. Tumor uptake of FLT will be imaged and measured with positron emission mammography (PEM), a PET scanner optimized for breast imaging with a significantly improved resolution compared to conventional whole-body PET imaging systems.
Conditions
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-07-08
- Last updated
- 2016-07-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00934401. Inclusion in this directory is not an endorsement.